1. Home
  2. VALU vs TRDA Comparison

VALU vs TRDA Comparison

Compare VALU & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Value Line Inc.

VALU

Value Line Inc.

N/A

Current Price

$37.55

Market Cap

340.4M

Sector

Finance

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.12

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VALU
TRDA
Founded
1931
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.4M
386.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VALU
TRDA
Price
$37.55
$11.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
3.1K
242.4K
Earning Date
12-15-2025
11-06-2025
Dividend Yield
3.42%
N/A
EPS Growth
6.17
N/A
EPS
2.26
N/A
Revenue
$34,801,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.16
P/E Ratio
$16.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.94
$4.93
52 Week High
$55.01
$19.93

Technical Indicators

Market Signals
Indicator
VALU
TRDA
Relative Strength Index (RSI) 54.29 73.37
Support Level $37.07 $10.40
Resistance Level $39.20 $11.24
Average True Range (ATR) 0.81 0.54
MACD 0.23 -0.01
Stochastic Oscillator 65.88 85.68

Price Performance

Historical Comparison
VALU
TRDA

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: